# Centre Eugène Marquis

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/centre-eugene-marquis/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 85 |
| Citations | 256,029 |
| City | Rennes |
| Country | FR |
| Description | Centre Eugène Marquis is a research organisation in Rennes, FR. OpenAlex records 3,890 works and 256,029 citations for it. 679 researchers list it as their most recent affiliation. |
| Homepage | http://www.centre-eugene-marquis.fr/en/ |
| OpenAlex ID | https://openalex.org/I4210110881 |
| Region | Brittany |
| Researchers | 679 |
| ROR ID | https://ror.org/01yezas83 |
| Type | facility |
| Works | 3,890 |

## University papers

- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://scholariq.org/papers/biomarker-analyses-in-the-phase-iii-ascent-study-of-sacituzumab-govitecan-versus/)
- [進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)](https://scholariq.org/papers/eso-esmo-abc-4/)
- [A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer](https://scholariq.org/papers/a-phase-ii-study-of-abemaciclib-in-patients-with-brain-metastases-secondary-to/)

## University top topics

Showing 8 of 25.

- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Medical Imaging Techniques and Applications](https://scholariq.org/topics/medical-imaging-techniques-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.